NovoCure【NVCR】銘柄情報

リアルタイムのストリーミング引用、アイデア、ライブディスカッションのハブ

プレミアム

通貨

30.80

買値

30.50

売値

84.37

出来高

1,693,696

30.46 日の範囲 31.52

11.70 52 週間の範囲 34.13

時価総額

3.333B

前日終値

30.40

始値

30.465

時刻

30.99

最終取引時間

財務取引量

US$ 52,567,754

VWAP

31.0373

平均取引量 (3 か月)

1,348,273

発行済株式数

108,201,434

配当利回り

PER

-16.11

1 株当たり利益 (EPS)

-1.91

歳入

509.34M

純利益

-207.04M

NovoCure Ltd serves in the healthcare sector of the United States. Its business involves commercial-stage oncology operations involving therapies to cure critical tumors. Its pipeline consists of Ovarian Cancer, Pancreatic Cancer, Non-Small Cell Lung Cancer, and Brain Metastasis. NovoCure derives it... NovoCure Ltd serves in the healthcare sector of the United States. Its business involves commercial-stage oncology operations involving therapies to cure critical tumors. Its pipeline consists of Ovarian Cancer, Pancreatic Cancer, Non-Small Cell Lung Cancer, and Brain Metastasis. NovoCure derives its major revenues in the United States. 詳細を表示

セクター

Surgical,med Instr,apparatus

業界

Surgical,med Instr,apparatus

ウェブサイト

www.novocure.com

本社

Jersey, Gbr

設立

NovoCure Ltd is listed in the Surgical,med Instr,apparatus sector of the ナスダック市場 with ticker NVCR. The last closing price for NovoCure was US$30.40. Over the last year, NovoCure shares have traded in a share price range of US$ 11.70 to US$ 34.13.

NovoCure currently has 108,201,434 shares in issue. The market capitalisation of NovoCure is US$3.29 billion. NovoCure has a price to earnings ratio (PE ratio) of -16.11.

Novocure annonce des résultats positifs de l'essai clinique de phase 3 PANOVA-3 sur les champs de traitement des tumeurs (TTFields) pour le cancer du pancréas

PANOVA-3 a atteint son objectif principal avec une amélioration statistiquement importante de la survie globale des patients atteints d'un adénocarcinome pancréatique non résécable et localement...

ノボキュア、膵がんに対する腫瘍治療電場療法（TTフィールド）の第3相臨床試験PANOVA-3のトップライン結果を発表

PANOVA-3試験でゲムシタビンおよびnab-パクリタキセルと併用したTTフィールドを一次治療として用いた切除不能な局所進行膵腺がん患者の全生存期間が統計的に有意に改善、主要評価項目を達成アメリカ、EU、日本...

Zai Lab and Novocure Announce Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer

PANOVA-3 met its primary endpoint with a statistically significant improvement in overall survival for patients with unresectable, locally advanced pancreatic adenocarcinoma treated in the...

Form 8-K - Current report

Novocure Announces Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer

PANOVA-3 met its primary endpoint with a statistically significant improvement in overall survival for patients with unresectable, locally advanced pancreatic adenocarcinoma treated in the first...

Novocure to Participate in Upcoming Investor Conferences

Novocure (NASDAQ: NVCR) announced today that management will participate in two upcoming investor conferences: Evercore ISI HealthCONx Conference on Wednesday, December 4, 2024, in Coral Gables...

Novocure Data at 2024 SNO Annual Meeting Highlights Product Innovation and Real-World Evidence for Tumor Treating Fields (TTFields) Therapy in Glioblastoma

Novocure (NASDAQ: NVCR) announced today that it will present new data for its Tumor Treating Fields (TTFields) therapy for glioblastoma at the 29th Annual Scientific Meeting and Education Day of...

FDA Approves Novocure’s Innovative HFE Transducer Arrays for Use With Optune Gio® for Glioblastoma

New flexible arrays are lighter, thinner and designed to improve comfort for Optune Gio users Novocure (NASDAQ: NVCR) announced today that the U.S. Food and Drug Administration (FDA) approved its...

Form 4 - Statement of changes in beneficial ownership of securities

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0.05	0.162601626016	30.75	34.13	29.79	1408113	31.91125459	CS
4	13.61	79.1739383362	17.19	34.13	17.16	1926502	28.83293627	CS
12	14.79	92.3797626483	16.01	34.13	14.17	1348273	22.28694961	CS
26	11.6	60.4166666667	19.2	34.13	14.17	1323903	20.11071264	CS
52	17.27	127.642276423	13.53	34.13	11.7	1329374	18.09382564	CS
156	-53.01	-63.2502088056	83.81	120.03	10.87	1096035	38.33953569	CS
260	-54.55	-63.9132981839	85.35	232.76	10.87	1009749	67.17234781	CS

NVCR - Frequently Asked Questions (FAQ)

What is the current NovoCure share price?

The current share price of NovoCure is US$ 30.80

How many NovoCure shares are in issue?

NovoCure has 108,201,434 shares in issue

What is the market cap of NovoCure?

The market capitalisation of NovoCure is USD 3.29B

What is the 1 year trading range for NovoCure share price?

NovoCure has traded in the range of US$ 11.70 to US$ 34.13 during the past year

What is the PE ratio of NovoCure?

The price to earnings ratio of NovoCure is -16.11

What is the cash to sales ratio of NovoCure?

The cash to sales ratio of NovoCure is 6.55

What is the reporting currency for NovoCure?

NovoCure reports financial results in USD

What is the latest annual turnover for NovoCure?

The latest annual turnover of NovoCure is USD 509.34M

What is the latest annual profit for NovoCure?

The latest annual profit of NovoCure is USD -207.04M

What is the registered address of NovoCure?

The registered address for NovoCure is NO 4 THE FORUM, GRENVILLE STREET, ST. HELIER, JERSEY, JE2 4UF

What is the NovoCure website address?

The website address for NovoCure is www.novocure.com

Which industry sector does NovoCure operate in?

NovoCure operates in the SURGICAL,MED INSTR,APPARATUS sector

出来高
値上がり率
値下がり率

銘柄コード	株価	出来高
MYSZMy Size Inc	US$ 4.2001 (211.12%)	121.03M
NVNINVNI Group Ltd	US$ 8.26 (209.36%)	78.06M
TPICTPI Composites Inc	US$ 2.45 (100.82%)	34M
ICGIntchains Group Ltd	US$ 8.77 (88.60%)	527.94k
HSDTHelius Medical Technologies Inc	US$ 0.884851 (84.34%)	121.95M
CYNCYNGN Inc	US$ 0.4603 (-71.41%)	27.5M
MTEMMolecular Templates Inc	US$ 0.1502 (-57.09%)	8.63M
PRFXPainReform Ltd	US$ 5.15 (-53.85%)	2.84M
GALTGalectin Therapeutics Inc	US$ 1.03 (-48.50%)	8.58M
BCABBioAtla Inc	US$ 0.6923 (-41.82%)	5.96M
EDBLEdible Garden AG Inc	US$ 0.24 (65.06%)	354.32M
APTOAptose Biosciences Inc	US$ 0.28 (64.51%)	305.1M
TNXPTonix Pharmaceuticals Holding Corporation	US$ 0.606999 (6.49%)	292.16M
NVDANVIDIA Corporation	US$ 134.70 (3.08%)	287.21M
PLTRPalantir Technologies Inc	US$ 80.55 (8.54%)	277.63M